Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Bronstein, Gewirtz & Grossman, LLC Is Investigating Viatris Inc. (VTRS) And Encourages Investors to Connect

VTRS

NEW YORK CITY, NY / ACCESS Newswire / March 9, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Viatris Inc. ("Viatris" or "the Company") (NASDAQ:VTRS). Investors who purchased Viatris securities are encouraged to obtain additional information and assist the investigation by visiting the firm's site: bgandg.com/VTRS.

Investigation Details

On February 27, 2025, Viatris issued a press release reporting its fourth quarter and full year 2024 financial results, which missed consensus estimates with respect to key metrics. In addition, Viatris provided lower-than-expected full-year guidance for 2025. Viatris also provided an update on remediation work at a manufacturing facility in India following receipt of a warning letter and import alert from the U.S. Food and Drug Administration, advising that it was "more than halfway through its remediation efforts and expects to be completed in a few months at which time the Company anticipates requesting FDA to conduct a reinspection of the facility." On this news, Viatris's stock price fell $1.71 per share, or 15.21%, to close at $9.53 per share on February 27, 2025.

What's Next?

If you are aware of any facts relating to this investigation or purchased Viatris securities, you can assist this investigation by visiting the firm's site: bgandg.com/VTRS. You can also contact Peretz Bronstein or his client relations manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC: 332-239-2660

There is No Cost to You

We represent investors in class actions on a contingency fee basis. That means we will ask the court to reimburse us for out-of-pocket expenses and attorneys' fees, usually a percentage of the total recovery, only if we are successful.

Why Bronstein, Gewirtz & Grossman

Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities fraud class actions and shareholder derivative suits. Our firm has recovered hundreds of millions of dollars for investors nationwide.

Follow us for updates on LinkedIn, X, Facebook, or Instagram.

Attorney advertising. Prior results do not guarantee similar outcomes.

Contact

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Nathan Miller
332-239-2660 | info@bgandg.com

SOURCE: Bronstein, Gewirtz & Grossman, LLC



View the original press release on ACCESS Newswire